Ronald J. Daniels - Dec 28, 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
Yi Ching Yau, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Dec 28, 2021
Transactions value $
$148,343
Form type
4
Date filed
12/30/2021, 07:17 PM
Previous filing
Jun 22, 2021
Next filing
Jun 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Purchase $150K +11.7K $12.73 11.7K Dec 28, 2021 Direct F1, F2
transaction BBIO Common Stock Sale -$150K -11.7K -100% $12.80 0 Dec 28, 2021 Direct F1, F3
transaction BBIO Common Stock Purchase $149K +10.4K $14.34 10.4K Dec 30, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions.
F2 Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
F3 Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.